IN RE APPLIED THERAPEUTICS SECURITIES LITIGATION — Entry #137: REPLY MEMORANDUM OF LAW in Support re: 133 MOTION to Approve Class Action Settlement, Plan of Allocation, Attorneys' Fees and Litigation Expenses
Case: IN RE APPLIED THERAPEUTICS SECURITIES LITIGATION nysd · 1:24-cv-09715
filed December 17, 2024
What this document is
Docket entry #137 · filed March 12, 2026
REPLY MEMORANDUM OF LAW in Support re: 133 MOTION to Approve Class Action Settlement, Plan of Allocation, Attorneys' Fees and Litigation Expenses . MOTION for Attorney Fees . . Document filed by Dr. Martin Dietrich. (Attachments: # 1 Exhibit 1 - Supplemental Declaration of Dawn M. Cody, # 2 Exhibit 2 - Proposed Final Judgment, # 3 Exhibit 3 - Proposed Final Judgment (Redline)).(Ruthizer, Joshua) (Entered: 03/12/2026)
Who is involved
- Adrian Alexandru
- Applied Therapeutics, Inc.
- Dr. Andrew Saw
- Dr. Martin Dietrich
- Emil Dezia
- Jesse Cole
- Justin Mac
- Mohammad Ali Ikram
- Otis D. Lucas, Jr.
- Riccardo Perfetti
- Robert Shane Reeder
- Shoshana Shendelman
- Sonam Dhondup
Why we have it
We follow this case because it names a company we track, although that company is not a party:
- Applied Digital: its former name “FLIGHT SAFETY TECHNOLOGIES INC” appears in a filing in this case.
…Co-Lead Counsel. $1.2 million. • Flight Safety Technologies, Inc., (D. Conn.). Rosen Lead Counsel. $1…
A free copy from the RECAP archive of federal court filings (mirrored at the Internet Archive), retrieved October 21, 2026. Federal court filings are public records.
Document text
9 page(s), 19,080 characters, converted from the PDF's text layer · plain text.
Full text
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 1 of 9
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
Case No. 1:24-cv-09715 (DLC) (VF)
IN RE APPLIED THERAPEUTICS
SECURITIES LITIGATION CLASS ACTION
REPLY MEMORANDUM OF LAW IN FURTHER SUPPORT OF LEAD PLAINTIFF’S
MOTION FOR FINAL APPROVAL OF CLASS ACTION SETTLEMENT, PLAN OF
ALLOCATION AND AN AWARD OF ATTORNEYS’ FEES AND LITIGATION
EXPENSES
WOLF POPPER LLP
Robert C. Finkel
Joshua W. Ruthizer
Emer Burke
Samuel Coffin
845 Third Avenue, 12th Floor
New York, New York 10022
(212) 759-4600
Lead Counsel for Lead Plaintiff Dr. Martin Dietrich and the Class
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 2 of 9
INTRODUCTION
Lead Plaintiff, Dr. Martin Dietrich, respectfully submits this Reply Memorandum of Law
(“Reply”) in further support of his Motion for Final Approval of Class Action Settlement, Plan of
Allocation, and Requests for Attorneys’ Fees and Expenses (ECF Nos. 133-135, the “Final
Approval Motion”). 1
FACTUAL AND PROCEDURAL HISTORY
A. Background on the Settlement
On February 12, 2026, Lead Plaintiff moved for final approval of the proposed Settlement
of this securities class action. If approved, the Settlement will resolve all claims against
Defendants in exchange for a cash payment of $15,000,000, and the $17,000 in Warrant Proceeds
paid upon the acquisition of Applied by third-party private company Cycle Pharmaceuticals
(“Cycle”) (discussed further infra at 2-3).
The Settlement (as set forth in the Stipulation) is a product of a diligent litigation
culminating in good-faith and arm’s-length negotiations between highly experienced counsel,
facilitated by a well-respected mediator, and made under distressed financial circumstances. As
described in Lead Plaintiff’s opening brief, the Settlement represents a highly favorable result for
the Class, recovering between 4% and 6.9% of maximum provable aggregate damages, depending
on the damages model used. These percentages are well-within the range of percentages of
maximum recoveries that courts typically approve in securities fraud class actions, and the
Settlement amounts to an excellent recovery given the attendant risks and distinct challenges of
continued litigation against a Company in such financial distress. ECF No. 134 at 10-12.
1
Unless otherwise defined herein, all capitalized terms are defined in the Stipulation of Settlement
dated November 20, 2025 (“Stipulation”), previously filed at ECF No. 126. Unless otherwise
noted, internal citations and quotation marks are omitted.
1
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 3 of 9
B. The Impact of Cycle Pharmaceuticals’ Acquisition of Applied on the
Warrants
After the execution of the Stipulation, Applied was acquired on February 3, 2026, by third-
party private company Cycle for $0.088 per share, plus the payment of a contingent value right
(“CVR”) depending on approval and commercialization of products under development by
Applied (the “Merger”). See ECF No. 134 at 6.
As part of the Settlement, Lead Plaintiff and Lead Counsel negotiated, for the benefit of
the Class, Warrants to purchase up to 1,000,000 shares of Applied common stock at a price of
$0.48 per share (the closing price of Applied common stock on August 19, 2025, the date of
settlement in principle). Lead Counsel negotiated the Warrants to provide the Class with upside
if Applied’s financial condition improved and its stock price increased. The Warrant Agreement
negotiated between the parties anticipated that, in the event Applied was acquired by a private
company and ceased to have publicly traded stock, then the Warrants would be converted to cash
pursuant to a Black Scholes Value formula.
The Warrant Agreement, which is an exhibit to the Stipulation, provided specific outcomes
in the event of a Fundamental Transaction (as that term is defined in the Warrant Agreement). One
such Fundamental Transaction was a “Change of Control,” which was defined as “any transaction
or series of transactions that, directly or indirectly, results in [Applied] not having [common stock]
registered under the 1934 Act and listed on an Eligible Market.” ECF No. 126, Ex. C ¶ 3(d). The
Merger meets the terms of a Change of Control.
Pursuant to the terms of the Warrant Agreement, “in the event of a Change of Control…”
the Holder [Lead Plaintiff/the Class] shall surrender this Warrant and shall be
entitled to receive from the Company or any Successor Entity, as of the date of
consummation of such Change of Control, the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion
of this Warrant, that is being offered and paid to the holders of Common Stock of
the Company in connection with the Change of Control, whether that consideration
2
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 4 of 9
be in the form of cash, stock or any combination thereof, or whether the holders of
Common Stock are given the choice to receive from among alternative forms of
consideration in connection with the Change of Control.
Id. The Warrant Agreement also sets forth the formula and inputs to calculate the Black Scholes
Value. Id.
The Stipulation defines “Warrant Proceeds” to include “any cash issued or paid in
connection with a Fundamental Transaction….” ECF No. 126 ¶ 1.67. The Stipulation also
requires Applied to pay “Warrant Proceeds to the Escrow Account…within thirty (30) calendar
days after … the effective date of a Fundamental Transaction…” Id. ¶ 2.8.
In sum, pursuant to the Warrant Agreement, as a result of the Merger, the Warrants must
be surrendered in exchange for the Black Scholes Value of the Warrants. And, pursuant to the
Stipulation, the Black Scholes Value is Warrant Proceeds, and those Warrant Proceeds were
required to be paid to the Escrow Account 30 days after the closing of the Merger.
After the closing of the Merger, Lead Counsel conferred with counsel to Applied
concerning the Change of Control and Black Scholes Value provisions of the Warrant Agreement.
As a result of those conversations, Cycle has transferred into the Settlement Fund the amount of
$17,000, which represents the Black Scholes Value of the Warrant based on the calculation set
forth in the Warrant Agreement.
C. Updates on the Notice Program
As detailed in the Final Approval Motion papers and the accompanying declaration from
Dawn C. Cody of Angeion Group LLC (“Angeion”) (ECF No. 135-1, “Cody Decl.”), the
Settlement Notice Program was implemented pursuant to the Court’s Preliminary Approval Order
dated November 19, 2026 (ECF No. 127). See ECF No. 134 at 7, 17; ECF No. 135-1 ¶¶ 5-32.
Lead Plaintiff now provides the Court with updates regarding the implementation of the notice
plan, as reflected in the Supplemental Declaration of Dawn M. Cody Regarding: (I) Mailing and
3
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 5 of 9
Emailing of Notice; (II) Report on Requests for Exclusion; and (III) Claims Received To Date,
dated March 12, 2026 (“Suppl. Cody Decl.”), and attached to this Reply as Exhibit 1.
In total, Angeion disseminated 60,382 copies of the Postcard Notice, including 39,864
Court-approved Postcard Notices and 20,518 link emails to potential Class Members and their
nominees. See Suppl. Cody Decl. ¶ 3. The Postcard Notice informed Class Members of a
summary of the terms of the proposed Settlement and that Lead Counsel would apply for an award
of attorneys’ fees in an amount not to exceed 20% of the Settlement Amount ($3,000,000), plus
litigation expenses not to exceed $50,000. See Cody Decl. Ex. A. The Postcard Notice also
apprised Class Members of: (1) their right to exclude themselves from the Class; (2) their right to
object to the terms of the Settlement or any of Lead Counsel’s Requests; (3) the February 26, 2026
deadline for filing objections; (4) the February 26, 2026 deadline for submitting requests for
exclusions; and (5) the April 8, 2026 deadline for submitting Claim Forms. Finally, the Postcard
Notice also advised Class Members how to obtain more information about the Settlement,
including directing Class Members to the Settlement Website, where they could obtain copies of
the Longform Notice and other important documents, identifying a toll-free number and a unique
email address where Class Members could contact the Claims Administrator, and providing Lead
Counsel’s contact information. See Cody Decl. Ex. A.
A toll-free telephone number and an interactive voice response system is active and will
remain active until the conclusion of the administration process. As of March 11, 2026, 69 callers
have called this number. See Suppl. Cody Decl. ¶¶ 8-12.
The Settlement Website is also active and will remain active until the conclusion of the
administration process. The Settlement Website was visited 3,196 times through March 11, 2026.
The Settlement Website contains downloadable copies of relevant documents, including the
4
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 6 of 9
Longform Notice, the Claim Form, and Lead Plaintiff’s Final Approval Motion. See Suppl. Cody
Decl. ¶¶ 16-21. This Reply will also be posted to the Settlement Website.
The Claims Administrator also continues to maintain a settlement specific email address -
[email protected] – through which Class Members can send inquiries.
Through March 11, 2026, Angeion has received 138 emails at this email address, and each email
received a response. See Suppl. Cody Decl. ¶¶ 13-15.
ARGUMENT
I. The Positive Reaction of the Class Supports Approval of the Settlement, the Plan of
Allocation, and the Fee and Expense Application
Lead Plaintiff advises the Court that in response to the 60,382 Postcard Notices distributed
to potential Class Members, no Class Member objected to any aspect of the Settlement, the Plan
of Allocation, or the Fee and Expense Application. Only one Class Member made a request for
exclusion from the Class. See Suppl. Cody Decl. ¶¶ 25-26.
This positive response from the Class provides additional support for the final approval of
the Settlement and the Plan of Allocation. See, e.g., Wal-Mart Stores, Inc. v. Visa U.S.A. Inc., 396
F.3d 96, 119 (2d Cir. 2005) (“[T]he favorable reaction of the overwhelming majority of class
members to the Settlement is perhaps the most significant factor in our Grinnell inquiry”); Maley
v. Del Global Techs. Corp., 186 F. Supp. 2d 358, 362 (S.D.N.Y. 2002) (“It is well-settled that the
reaction of the class to the settlement is perhaps the most significant factor to be weighed in
considering its adequacy. ... In fact, the lack of objections may well evidence the fairness of the
[s]ettlement.”); see also Marroquin Alas v. Champlain Valley Specialty of N.Y., Inc., No. 5:15-
CV-00441-MAD-TWD, 2016 WL 3406111, at *4 (N.D.N.Y. June 17, 2016) (“In the present
matter, no objections had been filed to the settlement agreement up until the time of the hearing
on June 9, 2016, and no Class Members appeared at the hearing. As such, the second Grinnell
5
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 7 of 9
factor weighs in favor of final approval.”); Kochilas v. Nat’l Merch. Servs., No. 1:14-CV-00311,
2015 WL 5821631, at *5 (E.D.N.Y. Oct. 2, 2015) (noting that there were no objections and
requests for exclusions received and holding that “[t]his overwhelmingly favorable response
recommends final approval.”); In re Luxottica Grp. S.p.A. Sec. Litig., 233 F.R.D. 306, 311
(E.D.N.Y. 2006) (A “[l]ack of objection is strong evidence of the settlement’s fairness.”).
The positive reaction of the Class as noted above also provides support to the
reasonableness of the Fee and Expense Application. See Vaccaro v. New Source Energy Partners
L.P., No. 15 CV 8954 (KMW), 2017 WL 6398636, at *8 (S.D.N.Y. Dec. 14, 2017) (“The fact that
no class members have explicitly objected to these attorneys’ fees supports their award.”); see also
Maley, 186 F. Supp. 2d at 374 (the lack of any objection to the fee request supported its approval).
In this case, Lead Counsel requests an award of attorneys’ fees equal to 20% of the
Settlement Fund, or $3 million plus 20% of the Warrant Proceeds, expenses in the amount of
$46,313.15, and interest on these amounts at the same rate earned by the Settlement Fund. In the
Final Approval Motion, Lead Counsel cited several examples of securities class action settlements
where a similar or greater percentage of the relevant settlement fund was awarded at a similar
procedural posture to this matter – while motions to dismiss were pending. See ECF No. 134 at
20. In addition to those cases, other courts in this Circuit have approved similar requests for
attorneys’ fees in cases where settlements were reached while motions to dismiss were pending.
See, e.g., In re Camelot Information Systems Inc. Sec. Litig., No. 1: 12-cv-00086-PGG, ECF No.
75 (S.D.N.Y. July 1, 2015) (approving attorneys’ fees of 30% of $11.8 million settlement fund
reached while motions to dismiss were pending); In re EVCI Career Colleges Holding Corp. Sec.
Litig., 2007 WL 2230177, at *17 (S.D.N.Y. July 27, 2007) (approving attorneys’ fees of 18% of a
$7.725 million settlement fund reached while motions to dismiss were pending); In re Merrill
6
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 8 of 9
Lynch & Co. Research Reports Sec. Litig., 246 F.R.D. 156, 176 (S.D.N.Y. 2007) (approving
attorneys’ fees of 24% of a $125 million settlement fund reached while motions to dismiss were
pending while noting that the fact that the settlement “occurred relatively early in litigation” did
not cut against the award of that percentage); Maley, 186 F. Supp. 2d at 368 (approving attorneys’
fees of 33.33% of $11.5 million settlement fund reached while motions to dismiss were pending,
while noting that “Courts in this and nearby Districts have recently awarded 33 1/3% in securities
class actions where there has been a significant monetary recovery early on in the litigation.”).
As noted in the opening papers, while this Court awarded attorneys’ fees of 15% in In re
Bumble, Inc. Sec. Litig., No. 22-cv-624 (DLC), ECF 93 (S.D.N.Y. Aug. 8, 2023), Lead Counsel
respectfully submits that this action had a higher degree of complexity than Bumble. See, e.g., ECF
No. 134 at 21; ECF No. 135, ¶ 138. In sum, this action alleges claims under the Securities
Exchange Act of 1934, for which scienter and loss causation are affirmative elements, and
concerns complex issues of falsity related to the FDA new drug approval process. Bumble alleged
strict liability and negligence-based claims under the Securities Act of 1933, and scienter and loss
causation were not affirmative elements. Lead Counsel respectfully submits that the complexity
of this action warrants an award of attorneys’ fees in the amount requested of 20%, which is also
less than the maximum amount of attorneys’ fees of 24% that Lead Plaintiff negotiated with Lead
Counsel, given the stage of the litigation when the Settlement was reached. ECF No. 135 ¶ 121;
ECF No. 135-2 ¶¶ 12-13.
CONCLUSION
For the reasons stated herein and in the Final Approval Motion (ECF Nos. 133-35), Lead
Plaintiff respectfully requests that the Court grant his Final Approval Motion and Fee and Expense
Application. A proposed Final Judgment is attached to this Reply as Exhibit 2. A redline
7
Case 1:24-cv-09715-DLC Document 137 Filed 03/12/26 Page 9 of 9
comparison showing changes from the proposed Final Judgment to the proposed Final Judgment
filed with the Stipulation (ECF No. 126 Ex. B) is attached as Exhibit 3.
Dated: March 12, 2026 Respectfully submitted,
WOLF POPPER LLP
By: /s/ Joshua W. Ruthizer
Joshua W. Ruthizer
[email protected]
Robert C. Finkel
[email protected]
Emer Burke
[email protected]
Samuel Coffin
[email protected]
845 Third Avenue, 12th Floor
New York, New York 10022
(212) 759-4600
Lead Counsel for Lead Plaintiff Dr. Martin
Dietrich and the Class
WORD COUNT CERTIFICATION
Pursuant to Southern District of New York Local Civil Rule 7.1(c), the undersigned hereby
certifies that this memorandum of law contains 2,308 words, excluding the caption, any index,
table of contents, table of authorities, signature blocks, or any required certificates. I utilized the
word count of the word-processing program used to prepare the document in order to obtain that
word count.
By: /s/ Joshua W. Ruthizer
Joshua W. Ruthizer
8
